LakeShore Biopharma Completes Going-Private Merger, Shares to Be Delisted
Summary
LakeShore Biopharma has completed its going-private merger, effective June 24, 2026, resulting in the company becoming a private entity and its shares being delisted from public trading.
Key Events
-
Merger Completed
The going-private merger became effective on June 24, 2026, making LakeShore Biopharma a wholly-owned subsidiary of Oceanpine Skyline Inc.
-
Shareholder Payout
Public shareholders will receive $0.066 in cash for each ordinary share.
-
Delisting Imminent
The company's trading symbols are expected to be removed by FINRA, and the shares will cease to be quoted on the OTC Pink tier.
-
Reporting Obligations End
LakeShore Biopharma intends to suspend its reporting obligations under the Exchange Act by filing Form 15 with the SEC.
Analysis
This filing confirms the finalization of LakeShore Biopharma's going-private merger, which became effective on June 24, 2026. As a result, the company is now a wholly-owned subsidiary of Oceanpine Skyline Inc., and its shares will cease to be quoted on the OTC Pink tier. Public shareholders will receive $0.066 per share, marking the end of the company's public trading. This is a definitive, thesis-altering event for investors.
At the time of this filing, LSBCF was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $0.03 to $2.80. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.